| 000 | 01119 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515180138.0 | ||
| 264 | 0 | _c20090806 | |
| 008 | 200908s 0 0 eng d | ||
| 022 | _a1945-7197 | ||
| 024 | 7 |
_a10.1210/jc.2009-0999 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKlibanski, Anne | |
| 245 | 0 | 0 |
_aDopamine agonist therapy in prolactinomas: when can treatment be discontinued? _h[electronic resource] |
| 260 |
_bThe Journal of clinical endocrinology and metabolism _cJul 2009 |
||
| 300 |
_a2247-9 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial | ||
| 650 | 0 | 4 |
_aDopamine Agonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xetiology |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 |
_aPituitary Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProlactinoma _xdrug therapy |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTumor Burden |
| 650 | 0 | 4 | _aWithholding Treatment |
| 773 | 0 |
_tThe Journal of clinical endocrinology and metabolism _gvol. 94 _gno. 7 _gp. 2247-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1210/jc.2009-0999 _zAvailable from publisher's website |
| 999 |
_c18999566 _d18999566 |
||